Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-CD73-anti-PD-1 bispecific antibody and application thereof

A bispecific antibody, CD73- technology, applied in the field of tumor therapy and molecular immunology, to increase the safety and efficacy, reduce the production of adenosine, and relieve the effects of inhibition

Pending Publication Date: 2021-10-22
AKESO BIOPHARMA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, immune checkpoint inhibitors have achieved great success in tumor immunotherapy, but also lead to a new toxicity spectrum due to off-target effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-CD73-anti-PD-1 bispecific antibody and application thereof
  • Anti-CD73-anti-PD-1 bispecific antibody and application thereof
  • Anti-CD73-anti-PD-1 bispecific antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0262] Example 1: Preparation of anti-CD73 antibody 19F3

[0263] 1. Preparation of hybridoma cell line LT014

[0264] The antigen used to prepare the anti-CD73 antibody is human NT5E-his (NT5E is Genbank ID: NP_002517.1, position: 1-552). The splenocytes of the immunized mice were fused with mouse myeloma cells to make hybridoma cells, and human NT5E (NT5E is GenbankID: NP_002517.1, position: 1-552)-Biotin was used as an antigen to conduct hybridoma cells Screening by indirect ELISA method to obtain hybridoma cells that can secrete antibodies specifically binding to CD73. For the hybridoma cells screened by the ELISA method, a stable hybridoma cell line was obtained through the limiting dilution method. The above hybridoma cell line was named hybridoma cell line LT014, and the monoclonal antibody secreted by it was named 19F3.

[0265] Hybridoma cell line LT014 (also known as CD73-19F3), which was deposited in the China Center for Type Culture Collection (CCTCC) on June 21...

Embodiment 2

[0268] Example 2: Sequence Analysis of Anti-CD73 Antibody 19F3

[0269] mRNA was extracted from the LT014 cell line cultured in Example 1 according to the method of the Bacteria Total RNA Extraction Kit (Tiangen, Cat. No. DP430).

[0270] According to Invitrogen III First-Strand Synthesis System for RT-PCR Kit Instructions Synthesize cDNA and perform PCR amplification.

[0271] The PCR amplification product was directly cloned by TA, and the specific operation was performed referring to the instructions of the pEASY-T1 Cloning Kit (TransgenCT101) kit.

[0272] The products of TA clones were directly sequenced, and the sequencing results were as follows:

[0273] The nucleic acid sequence (363bp) of the heavy chain variable region of 19F3 is shown in SEQ ID NO:1, and the encoded amino acid sequence (121aa) is shown in SEQ ID NO:2.

[0274] According to the IMGT numbering system, the sequence of the heavy chain CDR1 is shown in SEQ ID NO:3, the sequence of the heavy chain CD...

Embodiment 3

[0278] Example 3: Design, preparation and detection of humanized antibodies against human CD73

[0279] 1. Design of light chain and heavy chain sequences of humanized antibodies 19F3H2L3 and 19F3H2L2

[0280]According to the three-dimensional crystal structure of human CD73 protein (Hage T, Reinemer P, Sebald W. Crystals of a1:1 complex between human interleukin-4 and the extracellular domain of its receptor alpha chain. Eur J Biochem.1998; 258 (2): 831-6 ) and the sequence of the antibody murine antibody 19F3 obtained in Example 2, the antibody model was simulated by computer, and mutations were designed according to the model to obtain the variable region sequences of antibodies 19F3H1L1, 19F3H2L3 and 19F3H2L3, and the corresponding heavy chain variable region sequences were respectively 19F3H1, 19F3H2 (the amino acid sequences are shown in SEQ ID NO: 93, SEQ ID NO: 97), the light chain variable region sequences are respectively 19F3L1, 19F3L2, 19F3L3 (the amino acid sequen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an anti-CD73-anti-PD-1 bispecific antibody, a pharmaceutical composition thereof, and application.

Description

technical field [0001] The invention belongs to the field of tumor therapy and molecular immunology, and relates to an anti-CD73-anti-PD-1 bispecific antibody, its pharmaceutical composition and its application. Background technique [0002] Extracellular-5'-nucleotidase (Ecto-5'-nucleotidase), that is, CD73 protein, is a multifunctional glycoprotein with a protein molecular weight of 70KD encoded by the NT5E gene. phosphatidylinositol (GPI) is anchored on the cell membrane (Zimmermann H. 5'-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992; 285: 345-365). [0003] CD73 is widely distributed on the surface of human tissue cells. Current studies have found that CD73 is highly expressed in a variety of solid tumors, such as cancer cells in the tumor microenvironment, dendritic cells, regulatory T cells (Treg), natural killer cells (NK cells), Myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), etc. The expression of CD73 is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C12N15/13C12N5/20C07K16/28C07K16/40G01N33/573G01N33/574G01N33/68A61K39/395A61P35/00A61P7/06
CPCC07K16/2896C07K16/40C07K16/2818G01N33/573G01N33/57484G01N33/6893A61K39/3955A61K39/39558A61K39/39533A61K39/39566A61P35/00A61P7/06C07K2317/31C07K2317/565C07K2317/24C07K2317/92G01N2333/916G01N2333/70596G01N2333/70521G01N2800/22A61K2039/507G01N33/57492C07K2317/76C07K2317/71C07K2317/524C07K2317/64A61K2039/505A61K39/395C07K16/00C12N5/163G01N33/68G01N33/574C07K16/46C07K16/28C07K2317/55C07K2317/622C07K2317/73G01N2333/70503A61K47/6871A61K47/6849C07K2317/522C07K2317/567
Inventor 张鹏李百勇夏瑜王忠民
Owner AKESO BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com